US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
DE102004019539A1
(en)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drugs for the treatment of respiratory diseases
|
PL2422786T3
(en)
*
|
2004-04-22 |
2015-02-27 |
Boehringer Ingelheim Int |
New medicine combinations for treating respiratory diseases
|
JP2007537187A
(en)
*
|
2004-05-13 |
2007-12-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hydroxy-substituted benzofused heterocyclic compounds for use as beta agonists in the treatment of respiratory diseases
|
DE102004024451A1
(en)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder formulations for inhalation containing enantiomerically pure beta agonists
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
DE102004024453A1
(en)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New long-acting bronchodilators for the treatment of respiratory diseases
|
DE102004024454A1
(en)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
DE102004024452A1
(en)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosol formulation for the inhalation of beta agonists
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
DE102004045648A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New betamimetics for the treatment of respiratory diseases
|
GT200500281A
(en)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
ORGANIC COMPOUNDS.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
DE102005007654A1
(en)
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New long-acting betamimetics for the treatment of respiratory diseases
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DE102005030733A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
CA2618089A1
(en)
|
2005-08-08 |
2007-02-15 |
Argenta Discovery Ltd. |
Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
|
ES2530991T3
(en)
*
|
2005-08-15 |
2015-03-09 |
Boehringer Ingelheim Int |
Procedure for obtaining betamimetics
|
US20070088030A1
(en)
|
2005-10-10 |
2007-04-19 |
Barbara Niklaus-Humke |
Aerosol formulations for the inhalation of beta-agonists
|
US20070086957A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Thierry Bouyssou |
Combination of medicaments for the treatment of respiratory diseases
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
AU2006311060A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
EP1986644A1
(en)
*
|
2006-02-16 |
2008-11-05 |
Boehringer Ingelheim International GmbH |
Drug combinations for the treatment of respiratory tract diseases
|
PE20080142A1
(en)
*
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
ENANTHOMERICALLY PURE BETA-AGONISTS AND THEIR PREPARATION PROCEDURES
|
US8258141B2
(en)
|
2006-04-21 |
2012-09-04 |
Novartis Ag |
Organic compounds
|
WO2008017638A1
(en)
*
|
2006-08-07 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
|
UY30542A1
(en)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS
|
UY30543A1
(en)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
AEROSOL FORMULATION FOR INHALATION OF BETA- AGONISTS
|
ATE502943T1
(en)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
|
KR20090075714A
(en)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
Heterocyclic compounds as antiinflammatory agents
|
DE602007011670D1
(en)
|
2007-01-10 |
2011-02-10 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
|
ATE518847T1
(en)
*
|
2007-01-25 |
2011-08-15 |
Boehringer Ingelheim Int |
METHOD FOR PRODUCING BETAMIMETICS
|
EA200901489A1
(en)
|
2007-05-07 |
2010-04-30 |
Новартис Аг |
ORGANIC COMPOUNDS
|
AU2008334629B2
(en)
|
2007-12-10 |
2012-04-12 |
Novartis Ag |
Organic compounds
|
WO2009087224A1
(en)
|
2008-01-11 |
2009-07-16 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
EP2300010B1
(en)
|
2008-06-10 |
2015-03-04 |
Novartis AG |
Pyrazine derivatives as epithelial sodium channel blockers
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
NZ594157A
(en)
|
2008-12-30 |
2013-07-26 |
Pulmagen Therapeutics Inflammation Ltd |
Sulfonamide compounds for the treatment of respiratory disorders
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
CA2777245A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
UY33597A
(en)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
CA3029948C
(en)
*
|
2010-09-21 |
2021-06-15 |
Intekrin Therapeutics, Inc. |
Antidiabetic solid pharmaceutical compositions
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
EP2755967B1
(en)
|
2011-09-16 |
2015-10-21 |
Novartis AG |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
EP2793893A4
(en)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CN104245701A
(en)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
Combination products with tyrosine kinase inhibitors and their use
|
EP2906218B1
(en)
|
2012-10-09 |
2016-12-14 |
Boehringer Ingelheim International GmbH |
Beta-2-adrenoceptor agonist for the treatment of cough
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
ES2667424T3
(en)
|
2014-04-24 |
2018-05-10 |
Novartis Ag |
Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors
|
BR112016024533A8
(en)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
amino pyrazine derivatives as phosphatidylinositol 3-kinase or salt inhibitors, their use, and pharmaceutical composition and combination
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
AU2015294889B2
(en)
|
2014-07-31 |
2018-03-15 |
Novartis Ag |
Combination therapy
|
CN110062625A
(en)
|
2016-12-12 |
2019-07-26 |
勃林格殷格翰国际有限公司 |
Nintedanib by giving the method for treating interstitial lung disease with Ao Dateluo altogether
|
HRP20211915T1
(en)
|
2016-12-20 |
2022-03-18 |
Inke, S.A. |
Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
|
CN109096218B
(en)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
Oxydterol hydrochloride crystal form A and preparation method thereof
|
CN108997248B
(en)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
Crystal form B of ondarot hydrochloride and preparation method thereof
|
WO2020250116A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
US20220306617A1
(en)
|
2019-08-28 |
2022-09-29 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
WO2021252577A1
(en)
*
|
2020-06-09 |
2021-12-16 |
Anovent Pharmaceutical (U.S.), Llc |
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|